Table 1.
Baseline sociodemographic and clinical characteristics, and 1 L treatment
| Australia (N = 34) | Canada (N = 100) | Italy (N = 84) | UK (N = 62) | Overall (N = 280) | |
|---|---|---|---|---|---|
| General demographic and clinical characteristics | |||||
| Male gender, n (%) | 22 (64.7%) | 68 (68.0%) | 61 (72.6%) | 42 (67.7%) | 193 (68.9%) |
| Age (years) | |||||
| Mean (SD) | 65.7 (10.5) | 60.7 (11.0) | 60.6 (11.9) | 58.8 (14.0) | 60.9 (12.0) |
| Range | 42–83 | 33–85 | 34–83 | 26–81 | 26–85 |
| Ethnicity, n (%) | |||||
| Caucasian | 32 (94.1%) | 37 (60.7%) | 84 (100.0%) | 44 (83.0%) | 197 (84.9%) |
| Asian | 2 (5.9%) | 11 (18.0%) | - | 4 (7.5%) | 17 (7.3%) |
| Other | - | 13 (21.3%) | - | 5 (9.4%) | 18 (7.8%) |
| Unknown/missing | - | 39 | - | 9 | 48 |
| Smoking status, n (%) | |||||
| Current smoker | 6 (23.1%) | 13 (13.7%) | 11 (14.5%) | 7 (14.6%) | 37 (15.1%) |
| Ex-smoker | 9 (34.6%) | 38 (40.0%) | 37 (48.7%) | 22 (45.8%) | 106 (43.3%) |
| Non-smoker | 11 (42.3%) | 44 (46.3%) | 28 (36.8%) | 19 (39.6%) | 102 (41.6%) |
| Unknown/missing | 8 | 5 | 8 | 14 | 35 |
| Alcohol consumption, n (%)a | |||||
| Heavy | 1 (4.8%) | 6 (6.7%) | 2 (3.5%) | 3 (7.0%) | 12 (5.7%) |
| Occasional | 11 (52.4%) | 53 (59.6%) | 37 (64.9%) | 31 (72.1%) | 132 (62.9%) |
| Abstinent | 9 (42.9%) | 30 (33.7%) | 18 (31.6%) | 9 (20.9%) | 66 (31.4%) |
| Unknown/missing | 13 | 11 | 27 | 19 | 70 |
| Comorbidities, n (%)b | |||||
| None | 8 (23.5%) | 31 (31.0%) | 42 (50.0%) | 21 (33.9%) | 102 (36.4%) |
| Hypertension | 13 (38.2%) | 29 (29.0%) | 23 (27.4%) | 24 (38.7%) | 89 (31.8%) |
| Diabetes mellitus | 4 (11.8%) | 12 (12.0%) | 11 (13.1%) | 9 (14.5%) | 36 (12.9%) |
| Dyslipidemia | 7 (20.6%) | 14 (14.0%) | 6 (7.1%) | 6 (9.7%) | 33 (11.8%) |
| GI disease (other than gastric or GEJ cancer) | 3 (8.8%) | 11 (11.0%) | 6 (7.1%) | 3 (4.8%) | 23 (8.2%) |
| Cardiovascular disease | 5 (14.7%) | 13 (13.0%) | 7 (8.3%) | 5 (8.1%) | 30 (10.7%) |
| Disease history and characteristics | |||||
| Time since diagnosis (months), median (range) | 12.01 (5.09–43.41) | 7.79 (1.64–112.88) | 9.91 (2.83–102.83) | 9.76 (2.33–61.78) | 9.40 (1.64–112.88) |
| Location of metastasis, n (%)c | |||||
| None | 2 (5.9%) | 6 (6.0%) | 3 (3.6%) | 3 (4.8%) | 14 (5.0%) |
| Peritoneal | 10 (29.4%) | 34 (34.0%) | 32 (38.1%) | 18 (29.0%) | 94 (33.6%) |
| Liver | 21 (61.8%) | 40 (40.0%) | 33 (39.3%) | 24 (38.7%) | 118 (42.1%) |
| Bone | 3 (8.8%) | 13 (13.0%) | 11 (13.1%) | 5 (8.1%) | 32 (11.4%) |
| Lung | 7 (20.6%) | 23 (23.0%) | 20 (23.8%) | 9 (14.5%) | 59 (21.1%) |
| Other | 11 (32.4%) | 46 (46.0%) | 30 (35.7%) | 26 (41.9%) | 113 (40.4%) |
| Number of metastatic locations, n (%) | |||||
| 1 | 14 (43.8%) | 39 (41.5%) | 46 (56.8%) | 31 (52.5%) | 130 (48.9%) |
| 2 | 8 (25.0%) | 30 (31.9%) | 14 (17.3%) | 14 (23.7%) | 66 (24.8%) |
| 3 | 6 (18.8%) | 14 (14.9%) | 14 (17.3%) | 7 (11.9%) | 41 (15.4%) |
| 4+ | 4 (12.5%) | 11 (11.7%) | 7 (8.6%) | 7 (11.9%) | 29 (10.9%) |
| ECOG PS at initiation of 2 L treatment, n (%) | |||||
| Unknown | 9 (26.5%) | 32 (32.0%) | 9 (10.7%) | 5 (8.1%) | 55 (19.6%) |
| 0 | 7 (28.0%) | 7 (10.3%) | 19 (25.3%) | 12 (21.1%) | 45 (20.0%) |
| 1 | 17 (68.0%) | 41 (60.3%) | 45 (60.0%) | 38 (66.7%) | 141 (62.7%) |
| 2 | 1 (4.0%) | 18 (26.5%) | 11 (14.7%) | 5 (8.8%) | 35 (15.6%) |
| 3 | - | 2 (2.9%) | - | 2 (3.5%) | 4 (1.8%) |
| HER2 test, n (%) | |||||
| Not performed | 20 (58.8%) | 28 (28.0%) | 14 (16.7%) | 5 (8.1%) | 67 (23.9%) |
| Performed | 14 (41.2%) | 72 (72.0%) | 70 (83.3%) | 57 (91.9%) | 213 (76.1%) |
| Performed prior to 1 L initiation | 8 (61.5%) | 50 (76.9%) | 60 (87.0%) | 46 (85.2%) | 164 (81.6%) |
| Performed later in treatment | 5 (38.5%) | 15 (23.1%) | 9 (13.0%) | 8 (14.8%) | 37 (18.4%) |
| HER2 test positived | 3 (21.4%) | 17 (24.6%) | 15 (21.4%) | 11 (19.6%) | 46 (22.0%) |
| HER2 test negatived | 11 (78.6%) | 52 (75.4%) | 55 (78.6%) | 45 (80.4%) | 163 (78.0%) |
| HER2 test result not available | - | 3 | - | 1 | 4 |
| History of surgerye | 8 (24.2%) | 15 (15.5%) | 15 (18.3%) | 4 (6.6%) | 42 (15.4%) |
| History of radiotherapyf | 4 (12.9%) | 25 (25.5%) | 2 (2.5%) | 8 (13.3%) | 39 (14.5%) |
| 1 L anti-cancer drug therapy, n (%)g | |||||
| Monotherapy | 3 (8.8%) | 3 (3.0%) | 9 (10.7%) | 3 (4.8%) | 18 (6.4%) |
| Fluoropyrimidine | 1 (33.3%) | 3 (100.0%) | 4 (44.4%) | - | 8 (44.4%) |
| Taxane | 1 (33.3%) | - | 4 (44.4%) | 3 (100.0%) | 8 (44.4%) |
| Platinum | - | - | 1 (11.1%) | - | 1 (5.6%) |
| Other monotherapy | 1 (33.3%) | - | - | - | 1 (5.6%) |
| Combination therapy | 31 (91.2%) | 97 (97.0%) | 75 (89.3%) | 59 (95.2%) | 262 (93.6%) |
| Doublet chemotherapy | 7 (22.6%) | 25 (25.8%) | 30 (40.0%) | 12 (20.3%) | 74 (28.2%) |
| Fluoropyrimidine + platinum | 7 (22.6%) | 22 (22.7%) | 25 (33.3%) | 11 (18.6%) | 65 (24.8%) |
| Fluoropyrimidine + Irinotecan | - | 1 (1.0%) | 3 (4.0%) | - | 4 (1.5%) |
| Other doublet | - | 2 (2.1%) | 2 (2.7%) | 1 (1.7%) | 5 (1.9%) |
| Triplet chemotherapy | 22 (71.0%) | 71 (73.2%) | 42 (56.0%) | 43 (72.9%) | 178 (67.9%) |
| Fluoropyrimidine + platinum + anthracycline | 21 (67.7%) | 64 (66.0%) | 18 (24.0%) | 31 (52.5%) | 134 (51.1%) |
| Fluoropyrimidine + platinum + other | 1 (3.2%) | 7 (7.2%) | 23 (30.7%) | 12 (20.3%) | 43 (16.4%) |
| Other triplet | - | - | 1 (1.3%) | - | 1 (0.4%) |
a Heavy: > 3 (women) or > 4 (men) standard drinks/day; Occasional: < 3 or < 4 standard drinks/day, respectively; Abstinent = never drinks alcohol
b Only comorbidities present in ≥5% of the overall study population are listed
c Multiple responses were allowed
d Out of patients who had test; information on test was missing/unkown in 12 patients (7 from Canada, 1–3 from other countries), result was missing/unknown in 3 patients from Canada and 1 from the UK
e Surgical treatment of gastric/GEJ cancer; data were missing/unknown in 7 patients (1–3 in each country)
f Includes neoadjuvant and palliative radiotherapy; data were missing/unknown in 11 patients (2–4 in each country)
g Percentages for individual regimens are out of number of patients who received monotherapy or combination therapy, respectively
1 L first line, ECOG Eastern Cooperative Oncology Group, GEJ gastroesophageal junction, GI gastrointestinal, HER2 human epidermal growth factor receptor 2, SD standard deviation